GCP
PRVB

GSA Capital Partners’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

GSA Capital Partners’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-61,337
Closed -$276K – 2021
2022
Q3 		$276K Buy
+61,337
New +$279K 0.04% 990
2021
Q3 		– Sell
-44,897
Closed -$378K – 1881
2021
Q2 		$378K Buy
44,897
+15,513
+53% +$125K 0.04% 802
2021
Q1 		$308K Buy
+29,384
New +$413K 0.05% 633

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

GSA Capital Partners's PRVB Position: Q4 2022 in Review

GSA Capital Partners sold out of Provention Bio, Inc. Common Stock (PRVB) in Q4 2022, closing a stake of 61,337 shares — an estimated $276K sold.

GSA Capital Partners first reported a position in PRVB in Q1 2021 and held it in 3 quarters. The position peaked at $378K in Q2 2021. 133 funds tracked by Wall St. Rank hold PRVB as of Q4 2022.

  • GSA Capital Partners reported no remaining Provention Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • GSA Capital Partners sold 61,337 Provention Bio, Inc. Common Stock shares in Q4 2022, an estimated $276K.
  • GSA Capital Partners first reported a position in Provention Bio, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • GSA Capital Partners's Provention Bio, Inc. Common Stock position peaked at $378K in Q2 2021.
  • 133 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2022.

Based on GSA Capital Partners's 13F filing for Q4 2022, filed 13 Feb 2023.